Vivomicx

It is crucial to match the pharmacological effects of a new drug to the target cells in a tissue, however this is seldom accomplished at a cellular level. To assess the true effects of a drug is of particular importance if the target cells are underrepresented in an organ/tumor to be analysed. Vivomicx is able to tell you what the effects of a (new) drug are on the gene expression profiles of subsets of cells in the organ where the disease is located. These subset cells may either be the target cells for desired effects of the drug or the non-target cells to study bystander effects of undesired toxicity, thus better supporting your compounds go-no-go decisions.

Selected Publications

• Langenkamp E, Kamps JA, Mrug M, Verpoorte E, Niyaz Y, Horvatovich P, Bischoff R, Struijker-Boudier H, Molema G (2013). Innovations in studying in vivo cell behaviour and pharmacology in complex tissues - microvascular endothelial cells in the spotlight. Cell Tissue Res, 354(3):647-69.
  
• Dieterich LC, Mellberg S, Langenkamp E, Zhang L, Zieba A, Salomaki H, Teichert M, Huang H, Edqvist PH, Kraus T, Augustin HG, Olofsson T, Larsson E, Soderberg O, Molema G, Ponten F, Georgii-Hemming P, Alafuzoff I, and Dimberg A (2012), Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGF-beta2 in vascular abnormalization. J Pathol, 228 (3):378-390.
  
• Langenkamp E, Zwiers PJ, Moorlag HE, Leenders WP, St Croix B, and Molema G (2012). Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296. Anticancer Drugs; 23: 161-172.
  
• Langenkamp E, vom Hagen FM, Zwiers PJ, Moorlag HE, Schouten JP, Hammes HP, Gouw AS, and Molema G (2011), Tumor Vascular Morphology Undergoes Dramatic Changes during Outgrowth of B16 Melanoma While Proangiogenic Gene Expression Remains Unchanged. ISRN Oncology ePub:article ID 409308.
  
• Sikkema AH, de Bont ES, Molema G, Dimberg A, Zwiers PJ, Diks SH, Hoving EW, Kamps WA, Peppelenbosch MP, and den Dunnen WF (2011). VEGFR-2 signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells. Neuropathol Appl Neurobiol; 37(5): 538-548.
  
• Katta K, Boersema M, Adepu S, Rienstra H, Celie JW, Mencke R, Molema G, van Goor H, Berden JH, Navis G, Hillebrands JL, van den Born J (2013). Renal heparan sulphate proteoglycans modulate fibroblast growth factor 2 signaling in experimental chronic transplant dysfunction. Am J Pathol, 183(5):1571-84.
  
• Dickinson MG, Bartelds B, Molema G, Borgdorff MA, Boersma B, Takens J, Weij M, Wichers P, Sietsma H, and Berger RM (2011). Egr-1 expression during neointimal development in flow-associated pulmonary hypertension. Am J Pathol; 179: 2199-2209.
  
• van Meurs M, Fisheri NK, Wulfert FM, Asgeirsdottir SA, de Graaf IA, Satchell SC, Mathieson PW, Jongman RM, Kumpers P, Zijlstra JG, Heeringa P, and Molema G (2009). Shock induced stress induces loss of microvascular endothelial Tie2 in the kidney which is not associated with reduced glomerular barrier function. Am.J Physiol Renal Physiol 297 (2): F272-281.
  
• Asgeirsdottir SA, van SC, Kurniati NF, Zwiers PJ, Heeringa P, van MM, Satchell SC, Saleem MA, Mathieson PW, Banas B, Kamps JA, Rabelink TJ, van Zonneveld AJ, and Molema G (2012), MicroRNA-126 contributes to renal microvascular heterogeneity of VCAM-1 protein expression in acute inflammation. Am J Physiol Renal Physiol; 302(12):F1630-9.
  
• Yuan L, Sacharidou A, Stratman AN, Le Bras A, Zwiers PJ, Spokes K, Bhasin M, Shih SC, Nagy JA, Molema G, Aird WC, Davis GE, and Oettgen P (2011). RhoJ is an endothelial cell-restricted Rho GTPase that mediates vascular morphogenesis and is regulated by the transcription factor ERG. Blood; 118(4):1145-1153.
  
• Asgeirsdottir SA, Kamps JAAM, Bakker HI, Zwiers PJ, Heeringa P, van der Weide K, Van Goor H, Petersen AH, Morselt HW, Moorlag HE, Steenbergen E, Kallenberg CGM, and Molema G (2007), Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol Pharmacol 72(1): 121-131.